Vir Says Its Best-In-Class COVID-19 Antibody Profile Is Holding Up
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.
You may also be interested in...
Unused supply for the Lilly and Regeneron therapies has policymakers considering Medicare payment changes for providers managing outpatient infusion, but those may require legislation. National Academies of Sciences, Engineering and Medicine committee considers the ‘paradox of unused supply with a relatively scarce product’ and tries to dissect the challenges that may be contributing to the unexpected lack of take-up for the mABs.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.